BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 18656827)

  • 1. Should patients with Barrett's oesophagus be kept under surveillance? The case against.
    Barritt AS; Shaheen NJ
    Best Pract Res Clin Gastroenterol; 2008; 22(4):741-50. PubMed ID: 18656827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
    Armstrong D
    Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Surveillance for Barrett's oesophagus: worthwhile?].
    Kastelein F; Kuipers EJ
    Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barrett's oesophagus: Current controversies.
    Amadi C; Gatenby P
    World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R; O'Sullivan K; Quigley EM
    Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
    Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
    Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett's oesophagus: epidemiology, diagnosis and clinical management.
    Whiteman DC; Kendall BJ
    Med J Aust; 2016 Oct; 205(7):317-24. PubMed ID: 27681974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance in Barrett's oesophagus: a personal view.
    Basu KK; de Caestecker JS
    Postgrad Med J; 2002 May; 78(919):263-8. PubMed ID: 12151566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Barrett esophagus. Current situation of the risk and surveillance policy].
    Robaszkiewicz M
    Presse Med; 1994 Dec; 23(40):1846-8. PubMed ID: 7899314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barrett's oesophagus: optimal strategies for prevention and treatment.
    Fass R; Sampliner RE
    Drugs; 2003; 63(6):555-64. PubMed ID: 12656653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's oesophagus: a review of costs of the illness.
    Arguedas MR; Eloubeidi MA
    Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance.
    Rana PS; Johnston DA
    Dis Esophagus; 2000; 13(1):28-31. PubMed ID: 11005328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus.
    Inadomi JM
    Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):51-63. PubMed ID: 25743456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
    Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C
    Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance.
    Gudlaugsdottir S; van Blankenstein M; Dees J; Wilson JH
    Eur J Gastroenterol Hepatol; 2001 Jun; 13(6):639-45. PubMed ID: 11434588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.